Stereotaxis To Acquire Robocath In Deal Worth Up To $45 Mln

Stereotaxis agreed to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions. The deal expands Stereotaxis' presence in robotic medical devices and combines two companies focused on minimally invasive procedure automation. The announcement is modestly positive for the acquirer, though the immediate market impact is likely limited.

Analysis

Stereotaxis agreed to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions. The deal expands Stereotaxis' presence in robotic medical devices and combines two companies focused on minimally invasive procedure automation. The announcement is modestly positive for the acquirer, though the immediate market impact is likely limited.